title: Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
abstract: We compared use of a 3-class regimen (nevirapine [Nvp], stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.
authors.affiliation: Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France. odile.launay@avc.ap-hop-paris.fr
authors.forename: Odile
authors.initials: O
authors.lastname: Launay
authors.forename: Laurence
authors.initials: L
authors.lastname: Gérard
authors.forename: Laurence
authors.initials: L
authors.lastname: Morand-Joubert
authors.forename: Philippe
authors.initials: P
authors.lastname: Flandre
authors.forename: Sonia
authors.initials: S
authors.lastname: Guiramand-Hugon
authors.forename: Véronique
authors.initials: V
authors.lastname: Joly
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Agnès
authors.initials: A
authors.lastname: Certain
authors.forename: Claude
authors.initials: C
authors.lastname: Lévy
authors.forename: Stéphane
authors.initials: S
authors.lastname: Rivet
authors.forename: Christine
authors.initials: C
authors.lastname: Jacomet
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Aboulker
authors.forename: Patrick
authors.initials: P
authors.lastname: Yéni
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000627:therapeutic use; D019259:Lamivudine / Q000097:blood / Q000627:therapeutic use; D008297:Male; D019829:Nevirapine / Q000097:blood / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D018119:Stavudine / Q000097:blood / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D019259:Lamivudine; D019469:Indinavir; D019829:Nevirapine; D018119:Stavudine